Amgen Inc. (NASDAQ:AMGN) Stock Holdings Trimmed by Barlow Wealth Partners Inc.

Barlow Wealth Partners Inc. lessened its position in shares of Amgen Inc. (NASDAQ:AMGN) by 9.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,077 shares of the medical research company’s stock after selling 781 shares during the period. Barlow Wealth Partners Inc.’s holdings in Amgen were worth $1,903,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Capital Performance Advisors LLP bought a new position in Amgen in the third quarter worth about $25,000. Legacy Investment Solutions LLC bought a new stake in shares of Amgen in the 3rd quarter worth approximately $29,000. Hershey Financial Advisers LLC acquired a new position in Amgen during the 2nd quarter valued at approximately $30,000. Matrix Trust Co bought a new position in Amgen during the 3rd quarter worth $36,000. Finally, Livelsberger Financial Advisory acquired a new stake in Amgen in the third quarter worth $56,000. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on AMGN. Leerink Partners reduced their target price on shares of Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Citigroup cut their target price on Amgen from $335.00 to $310.00 in a research note on Wednesday, November 27th. Barclays lifted their price objective on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research note on Monday, October 7th. StockNews.com lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Finally, Wells Fargo & Company dropped their target price on Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a report on Friday, January 10th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $314.91.

Amgen Stock Performance

Shares of AMGN opened at $274.81 on Wednesday. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The company has a market capitalization of $147.72 billion, a PE ratio of 35.19, a PEG ratio of 2.78 and a beta of 0.56. The company’s 50 day moving average price is $272.95 and its 200 day moving average price is $306.92.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. Amgen’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the prior year, the business posted $4.96 earnings per share. Research analysts expect that Amgen Inc. will post 19.57 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.46%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. Amgen’s payout ratio is currently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.